Piper Jaffray analyst Christopher Raymond remains a buyer of Aimmune Therapeutics shares after hosting an investor day with management. The latest iteration of the bear thesis around Aimmune now argues that issues around treatment logistics, access, and durability of treatment will hamper uptake upon Palforzia approval, Raymond tells investors in a research note. However, the analyst believes that many components of this thesis "will be dispelled." With his survey work boding well for Palforzia uptake and durability, he keeps an Overweight rating on Aimmune with a $60 price target.